gefitinib has been researched along with montelukast in 7 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (montelukast) | Trials (montelukast) | Recent Studies (post-2010) (montelukast) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,965 | 598 | 777 |
| Protein | Taxonomy | gefitinib (IC50) | montelukast (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 3.197 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 4.702 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 3.488 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.689 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 3.919 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.434 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.7 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 8.045 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.434 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 5.279 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 6.626 | |
| Substance-K receptor | Homo sapiens (human) | 3.822 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.689 | |
| Thromboxane-A synthase | Homo sapiens (human) | 1.525 | |
| D(3) dopamine receptor | Homo sapiens (human) | 7.747 | |
| Delta-type opioid receptor | Homo sapiens (human) | 4.795 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 6.256 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.434 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.601 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.856 | |
| Leukotriene C4 synthase | Homo sapiens (human) | 5 | |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | 0.0015 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kim, KS; Liu, W; Prakash, A; Zhang, C; Zhu, N | 1 |
1 review(s) available for gefitinib and montelukast
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for gefitinib and montelukast
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Targeting E. coli invasion of the blood-brain barrier for investigating the pathogenesis and therapeutic development of E. coli meningitis.
Topics: Acetates; Animals; Anti-Bacterial Agents; Blood-Brain Barrier; Brain; Ceftriaxone; Cells, Cultured; Cyclopropanes; Cysteine; Drug Therapy, Combination; Endothelial Cells; ErbB Receptors; Escherichia coli; Female; Gefitinib; Humans; Infant, Newborn; Leukotriene Antagonists; Leukotrienes; Male; Meningitis, Escherichia coli; Mice; Permeability; Phospholipases A2, Cytosolic; Quinolines; Sphingosine-1-Phosphate Receptors; Sulfides | 2020 |